TY - BOOK ID - 134287616 TI - Precision Medicine in Solid Tumors AU - Dey, Nandini AU - De, Pradip PY - 2022 PB - Basel MDPI Books DB - UniCat KW - Medicine KW - Oncology KW - pediatric tumors KW - tumor mutational burden KW - TMB KW - whole-exome sequencing KW - gene panel sequencing KW - immune checkpoint inhibitors KW - glioblastoma prognosis KW - overall survival KW - extent of resection KW - random forest KW - Decision tree KW - personalized precision oncology KW - circulating free DNA KW - liquid biopsy KW - epidermal growth factor receptor KW - tyrosine kinase inhibitor KW - osimertinib KW - comprehensive genomic profiling KW - molecular genotyping KW - intratumor heterogeneity KW - multiple biopsies KW - tumor evolution KW - clonality classification KW - strategic therapeutic intervention KW - thymoma KW - driver mutation KW - sequencing KW - molecular barcoding KW - EGFR mutation KW - EGFR-TKI KW - cfDNA KW - NGS KW - digital enrichment KW - next-generation sequencing KW - solid cancer KW - universal health-care system KW - precision medicine KW - presumed germline findings KW - clinical guideline KW - non-small cell lung cancer KW - outcome KW - adjuvant chemotherapy KW - anaplastic lymphoma receptor tyrosine kinase KW - HNSCC KW - ctDNA KW - tDNA KW - DDR genes KW - PARP inhibitors KW - new drug development KW - next-generation sequencing (NGS) KW - open data KW - regulatory reform KW - tumor profiling test KW - triple-negative breast cancer (TNBC) KW - breast cancer KW - targeted therapy KW - TNBC subtypes KW - immunotherapy KW - cancer KW - screening KW - smoking KW - electronic records KW - PD-L1 KW - cancer-associated fibroblasts KW - resistance KW - chemotherapy KW - CTC KW - immunocytochemistry KW - parallel double-detection KW - laboratory-friendly KW - n/a UR - https://www.unicat.be/uniCat?func=search&query=sysid:134287616 AB - In the era of precision medicine, the use of molecularly targeted therapies in selected patients has led to a paradigm change in cancer treatment. Multiple studies have demonstrated the benefits of therapies that are chosen based on the molecular profile of the tumor and also from the liquid biopsy. With genomics' increasing ability, a routine transcriptomics analysis of advanced/metastatic cancers is now feasible in most cancer hospitals, including community cancer centers. This is an unprecedented shift in the management of cancers irrespective of their organ types, which not only improved the outcome but also opened several new avenues in research and practice, such as immune-check-point inhibitors, tumor-TME co-evolution in the development of resistance, longitudinal liquid biopsies, biomarkers screening and the management of electronic medical records.This book brings together these crucial areas of investigation. The research presented here attempts to address the current issues to provoke thoughts for the future. The future of precision medicine will have to embrace a shift from in vitro, in vivo/PDX models for the mechanistic study to a more functional test based on the scientific interrogation of genomic data, in the form of functional precision medicine. We will also have to combat the element of noise in the multitudes of data and impart the regulatory structure to make judicious use of the data. The expectations for functional precision medicine are high. We aspire to witness a tremendous improvement in patient outcomes, from better to best, down the road that will match the clinical guidelines. ER -